Clinical Trial Search

Primary: Change From Baseline in Trough Seated Systolic Blood Pressure (SBP) at Week 8 — -47.5; -36.9; -43.2 mmHg (millimeters of mercury) — p=<0.0001

Primary: Pain Intensity Difference (PID) at 15 Minutes Post-treatment (PID15) — 0.88; 0.76 Units on scale — p=0.0004

Primary: Change From Baseline in the Toronto Western Spasmodic Torticollis Rating Scale (TWSTRS) -Total Score at Week 4 After Injection of the Main Period - Xeomin (240 Units)…

Primary: Percentage of Subjects in Clinical Remission at Week 6 — 31.6; 25.4 percentage of subjects

Primary: Proportion of Relapsing Multiple Sclerosis (RMS) Subjects Rating the Single-use Autoinjector as 'Easy to Use' or 'Very Easy to Use' for Self-injection in a User Trial…

Primary: Number of Participants With a Sustained Pain-free (SPF) Response From 2 to 24 Hours Post-dose — 10; 26; 18 participants — p=0.378

Primary: Number of Participants With Gastric Ulcer Confirmed by Endoscopy — 9; 50 Participants — p=0.001

Primary: Number of Participants With Gastric Ulcer Confirmed by Endoscopy — 15; 51 Participants — p=0.001

Primary: Changes in Gastrointestinal Symptom Severity and/or Health-related Quality of Life After Conversion From MMF to Enteric Coated Mycophenolate Sodium — -0.46 Change in…

Primary: Mean Change From Baseline in HIV Ribonucleic Acid (RNA) at Week 24 — -1.86; -1.52; -1.89 log10 c/mL

Primary: Number of Participants With the Indicated Number of Adverse Events (AEs) and Serious Adverse Events (SAEs) — 365; 109; 213; 106 participants

Primary: Number of Participants Who Achieve a Greater Than or Equal to 75% Improvement in Psoriasis Area and Severity Index (PASI) Score — 111; 111 Participants

Primary: Percentage of Dyads (Participant and Caregiver or Parent) Reporting no Difference or Easier to Use for New Genotropin Mark VII Injection Pen Compared to Pre-study…

Primary: Overall Survival — 12.7; 15.1 Months — p=<0.0001

Primary: ICDAS Severity Value — 17; 22; 278; 273 teeth — p=0.1126